PRESS RELEASES

Found 258 Results
Page 24 of 26

BioAlliance Pharma announces a new positive DSMB recommendation to continue its Phase III clinical trial with Livatag® in primary liver cancer


BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, […]

04/14/2014


Publication of the 2013 Registration Document


BioAlliance Pharma SA (Euronext Paris – BIO), Société d’innovation spécialisée dans le développement de médicaments visant des pathologies orphelines en […]

Tags:

04/08/2014


BioAlliance Pharma Announces Shareholders’ Meeting and Approval of all resolutions


BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, […]

Tags:


BioAlliance Pharma signs a new licensing agreement with Daewoong Pharmaceutical Co., Ltd. for Sitavig®’s commercialization in South Korea


BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, […]

Tags:

04/02/2014


BioAlliance Pharma provides an update on its partnerships for Loramyc®/Oravig®


BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, […]

Tags:

04/01/2014


BioAlliance Pharma collaborates with Penn Pharma on the industrial development of Validive®


BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, […]

03/31/2014


Sitavig® Licensing Strategy: Execution of licensing agreement with Innocutis for North America and Positive opinion from French and German Health Authorities for Marketing Authorization


BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company dedicated to the development of orphan oncology products, announced major […]

03/19/2014


BioAlliance Pharma provides updates on its major achievements and reports 2013 consolidated financial results


2013: Significant progress on key strategic programs • Livatag® phase III (ReLive): European expansion and authorization from the FDA to […]

Tags:

02/27/2014


Strengthening and extension of the industrial protection of Livatag® until 2031 – First delivery of a new European patent


BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company dedicated to the development of orphan oncology products, announced today […]

02/18/2014


BioAlliance Pharma’s partner, Sosei, announces a partnership with FUJIFILM Pharma for commercialization rights for Loramyc® in Japan


Paris, February 4, 2014 – BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company dedicated to the development of orphan […]

02/04/2014


Page 24 of 26